Isradipine
Isradipine is a second-generation dihydropyridine calcium channel blocker. It has been found to protect against stroke and brain ischemia in rat models of hypertension. Research has also shown that isradipine influences amyloid-beta production in addition to components of the cav1.2-ptau-autophagy pathway and thereby may be useful in the treatment of Alzheimer’s disease. Furthermore, it has been found to protect striatal dopaminergic terminals and parent substantia nigra pars compacta cell bodies against intrastriatal injection of the toxin 6-hydroxydopamine, and so may also be an effective treatment of Parkinson’s disease.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18935753
| Cas No. |
75695-93-1 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H21N3O5 |
| Formula Wt. |
371.39 |
| IUPAC Name |
4-(2,1,3-Benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester |
Lee HA, Hyun SA, Park SG, et al. Comparison of electrophysiological effects of calcium channel blockers on cardiac repolarization. Korean J Physiol Pharmacol. 2016 Jan; 20(1):119-127. PMID: 26807031.
Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: the case for isradipine. Biochim Biophys Acta. 2011 Dec; 1812(12): 1584-1590. PMID: 21925266.
Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis. 2011 Aug; 43(2): 364-371. PMID: 21515375.
